STUDY OF DEMOGRAPHIC ANALYSIS, CLINICAL CHARACTERISTICS, DIAGNOSIS, MANAGEMENT AND COMPLICATIONS IN COVID-19 PATIENTS by PAVAN KUMAR M et al.
Vol 14, Issue 12, 2021
Online - 2455-3891 
Print - 0974-2441
STUDY OF DEMOGRAPHIC ANALYSIS, CLINICAL CHARACTERISTICS, DIAGNOSIS, 
MANAGEMENT, AND COMPLICATIONS IN COVID-19 PATIENTS
PAVAN KUMAR M*, REVATHI G, SUPRAJA K, SECHANA K
Department of Pharm-D, Malla Reddy Institute of Pharmaceutical Sciences, Affiliated to Jawaharlal Nehru Technological University 
Hyderabad, Hyderabad, Telangana, India. Email: pavankumarpk093@gmail.com
Received: 30 August 2021, Revised and Accepted: 25 October 2021
ABSTRACT
Objective: This study aims to study the demographic analysis, clinical characteristics, diagnosis, and management in COVID-19 patients and assess 
the complications in COVID-19 patients.
Methods: A retrospective observational single centered study is carried out to study the demographic analysis, clinical characteristics, diagnosis, 
management, and complications in COVID-19 patients.
Results: Among 100 COVID-19 patients, 58% were male and 42% were female. Percentages of age group between 60–70 years (27%), 50–60 (20%), 
40–50 (16%), 70–80 (16%), 30–40 (8%), 20–30 (5%), 80–90 (4%), and 10–20 (4%). Co-morbidities were diabetes (44%), hypertension (HTN) 
(28%), coronary artery disease (21%), thyroid (19%), chronic obstructive pulmonary disease (12%), anemia (8%), and renal impairment (4%). Signs 
and symptoms were fever (88%), cough (80%), shortness of breath (72%), fatigue (68%), myalgia (60%), loss of appetite (52%), cold (24%), loss of 
smell and taste (20%), diarrhea and vomiting (12%). (97%) of the patients had two or more symptoms. Diagnostic test include reverse transcription 
polymerase chain reaction (RT-PCR) (100%), high-resolution computed tomography (HRCT) (100%), O2 saturation (99%), D-dimer (65%), c-reactive 
(60%), Procalcitonin (60%), and also lactate dehydrogenase, interleukin-6, prothrombin time, international normalized ratio, ferritin, complete 
blood count, white blood cell. Treatment includes antiviral (100%), antibiotics (100%), corticosteroids (73%), immunosuppressant (54%), and 
antihypertensive, antidiabetic, antiplatelets, bronchodilators, vitamins, and mineral supplements.
Conclusion: COVID-19 infects the males more and average ages of 65 years are at risk. HTN and diabetes were most common co-morbid condition. 
Fever and cough are major followed by weakness sob and cold. RT-PCR and HRCT are accurate tool to detect COVID-19. Although standard treatment 
is not yet available antibiotics and antiviral are used followed by corticosteroids. The majority of the patients have mild and moderate injection and 
with the lowest death rate. Older age and co-morbid conditions are major risk factors.
Keywords: COVID-19, Fever, Cough, High-resolution computed tomography, Reverse transcription polymerase chain reaction, Hypertension, 
Corticosteroids, Interleukin-6, Immunosuppressant.
INTRODUCTION
A coronavirus takes its name from its microscope appearance. The word 
corona suggests “crown,” and when almost studied, the circular virus 
has a “crown” of proteins, which in every manner are termed peplomers, 
sticking away or extending from the center [1]. Mostly, it spreads to 
people through cough and sneezing outlets. Respiratory failure might 
occur and cause mortality as the alveolar illness advances. Angiotensin-
converting enzyme 2 may also be a way for the virus to attack the heart, 
which causes acute heart damage. The poorest prognosis is among 
those with established cardiovascular problems [1]. The causes of re-
infection may be short-term immunity or residues of the virus from the 
initial infection and changes in the genomic sequence of this virus [2]. 
Pathophysiology of COVID-19 shows the mechanism of severe acute 
respiratory syndrome coronavirus 2 invasion into host cell using α, β, γ, 
and δ receptors where the virus attaches to the host receptor through 
endocytosis and replication of viral RNA takes place after entering into 
the core leading to production of more viral proteins [3]. Symptoms 
may occur 2–14 days later. Common symptoms may include: Cough, 
Fever, Fatigue, and COVID-19 may involve a loss of taste or smell as the 
principal indication [4]. Contaminated secretions can be provisionally 
recognized by reverse-transcription polymerase chain reaction (RT-
PCR). Chest computed tomography (CT) scanning may be effective in 
persons with high clinical suspicion of infection for COVID-19 diagnosis. 
Treatment includes several class of drugs such as anti-retro viral 
agents, immune enhancing agents, immunosuppressants, non steroid 
anti-inflammatory drugs, antibiotics, and other drugs are also used 
depending on the condition of the patients and co-morbidities which 
include antiplatelets, anticoagulants, antihypertensive, antianginas, 
bronchodilators, diuretics, proton pump inhibitors, histamine-2 
receptor antagonists, antidiabetic, vitamin-c, vitamin-d3, zinc, and 
calcium supplements [5].
METHODS
This is a retrospective observational single centered study conducted 
for 4 months from March 2021 to June 2021 in 650 bedded Malla 
Reddy Narayana Multispeciality Hospital-COVID Department. Suraram, 
Hyderabad, Telangana. The study protocol was prepared, submitted, 
and approved by the hospital ethics committee (Regd No: ECR/227/
Inst/AP/2013/RR-16). The study was initiated after the ethics 
approval. Evaluation of data was conducted in 100 COVID-19 patients.
Study criteria
Inclusion criteria
•	 Patients with COVID positive
•	 All patients confirmed by RT-PCR and were diagnosed as having 
COVID-19 according to WHO interim guidelines
•	 All patients who underwent chest high-resolution CT (HRCT) and a 
complete panel of routine laboratory tests include complete blood 
count, Urine analysis, blood chemistry, and blood coagulation 
function
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•	 C-reactive protein (CRP)
•	 In-patients
•	 Patients of both genders of all age groups.
Exclusion criteria





In our retrospective study, a total of 100 cases were collected in 
4 months of which 42% were female patients and 58% patients were 
male.
Age-wise distribution
A total of 100 cases who have admitted in the COVID department of the 
tertiary care hospital were examined during the study period based on 
the inclusion and exclusion criteria.
Age wise distributions of the cases are given in the table with the class 
interval of 10 years and their percentage.
Existing comorbid conditions
Any co-morbid conditions present among the 100 patients were 
recorded and analyzed. The table shows the most common co morbid 
conditions present among patients at the time of our study, and they 
include inflammatory bowel disease, hypertension (HTN), diabetes, 
coronary artery disease (CAD), chronic obstructive pulmonary disease 
(COPD), and renal disorders. Other existing conditions that were found 








1. Unilateral lung involvement-73%
2. Bilateral lung involvement-27%
3. Single lesions-8%
4. Multiples lesions-5%
5. Ground glass opacities-33%
6. Ground glass nodules-12%





Table 3: Existing co-morbid conditions among 
COVID‑19 patients








Renal disorders 3 4
IBD: Inflammatory bowel disease, HTN: Hypertension, DM: Diabetes mellitus, 
CAD: Coronary artery disease, COPD: Chronic obstructive pulmonary disease
AQ4
Table 4: Table representing clinical characteristics of 
COVID‑19 patients
Symptom Percentage








Loss of taste and smell 20
Diarrhea 12
Two or more symptoms 97
SOB: Shortness of breath
AQ4












PT and INR 25
Others 53
RT-PCR: Reverse transcription polymerase chain reaction, HRCT: High-resolution 
computed tomography, CRP: C-reactive protein, LDH: Lactate dehydrogenase, IL: 
Interleukin-6, PT: Prothrombin time, INR: International normalized ratio
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Table 2: Age-wise distribution of subjects
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1. Unilateral lung involvement- 73%
2. Bilateral lung involvement- 27%
3. Single lesions- 8%
4. Multiples lesions- 5%
5. Ground glass opacities- 33%
6. Ground glass nodules- 12%












Procalcitonin - (0.5–2 ng/ml)
1. Increased- 39%
2. Normal- 61%.
Serum ferritin - (30–400 pg/ml)
1. Increased- 23%
2. Normal- 77%.
Interleukin (IL)-6 (up to 4.4 pg/ml)
1. Increased- 19%
2. Normal- 81%.
Lactate dehydrogenase - (98–192 IU/L)
1. Increased- 84%
2. Normal- 16%.









Complete blood count (CBC) which includes hematology, white blood 
cells, dendritic cell, platelet count, urine analysis, renal function tests, 
liver function test.
Severity
Severity of the COVID-19 patients was categorized according to the 
computed tomography (CT) severity score.
Treatment
Antibiotics: (100%)
Cephalosporins such as ceftriaxone, cefoperazone, doxycycline, 




2. ticarcillin+ clavulanic acid
3. piperacillin + tazobactum.
Antivirals: (100%)
Remdesvir, oseltamavir, hydroxychloroquine, lopinavir, favipiravir, 
ivermectin.
Corticosteroids: (73%)




i. Anti-platelets: aspirin, clopidogrel. Ticagrelor
ii. Anti-coagulants: heparin, enoxaparin, rivaroxaban. (63%)
iii. Anti-hypertensive: statins, beta blockers, alpha blockers, sildenafil. 
(28%)
Figure 2: Graphical representation of existing co-morbid 
conditions among COVID‑19 patients
AQ3
Figure 1: Pictorial representation of the gender-wise distributionAQ3
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group of 60–70 years. Diabetes mellitus and HTN were the most common 
co morbidities among the individuals infected with COVID-19 which 
was similar to other study [7]. Fever and cough were the major clinical 
presentations followed by SOB, myalgia, cold, and also loss of taste and 
smell along with some other symptoms were reported. Almost 97% of 
the individuals have been presented with two or more symptoms. RT-PCR 
and CT scan are the standard diagnostic tests for detecting COVID-19.
COVID-19 standard therapy is still not available, although most patients 
are administered with antibiotics and antiviral medicines. Corticosteroids 
and immunosuppressants respectively with a proportion. Antiplatelets, 
anti-hypertensive medicines, anti-angina medicines, diuretics, 
bronchodilators, anti-diabetic medicines, pump-proton inhibitors, 
histamine-2 antagonists receptor, vitamins and mineral supplements 
such as vitamin C, vitamin-D3, zinc and calcium are also administered. 
The majority of patients received oxygen therapy followed by non-
invasive ventilation, invasive air ventilation, high nasal flow oxygenation, 
CRRT. According to the CT severity score, the severity of patients with 
COVID-19 was found to indicate a moderate (48%), intermediate (39%), 
severe (10%), and critically sick patients (3%) leading to death.
From the clinical results we can show that (97%) of the patients were 
released and (3%) of the patients were killed. The average hospital 
stay time might be 15–20 days. During this investigation, it has been 
observed that significant cardiopulmonary arrest and respiratory failure 
are major consequences of COVID-19 during hospital stays which lead 
to serious responses or even death. There may also be involvement of 
acute respiratory distress syndrome, COVID pneumonia, lung fibrosis, 
and septic shock. These difficulties that have been observed in our 
investigation may potentially be caused by existing morbid illnesses 
such as DM and HTN. These findings were likewise comparable in the 
Lin Huang et al. investigation [8].
iv. Anti-anginal: nitroglycerine, amiodarone, nicorandil. (23%)
v. Diuretics: furosemide, spironolactone. (4%)
vi. Bronchodilators: budesonide, levosalbutamol, n-acetylcysteine, 
ambroxol + levosalbutamol, acetylcysteine + acebrophylline, 
glycopyronium. (12%)
vii. Anti-diabetics: human octrapid insulin, metformin hydrochloride. 
(44%)
viii. Anti-fungal: amphotericin-B, fluconazole. (rare)
ix. PPI and H2RA: pantoprazole, omeprazole, rabeprazole, ranitidne. 
(100%)
x. Vitamins and minerals: vitamin-c, vitamin-d3, zinc acetate, calcium 
supplements (100%).
xi. Intensive care treatment:
1. O2 Therapy: 35%
2. Non invasive ventilation: 6%
3. Invasive ventilation: 5%
4. HNFO: 1%
5. ECMO: 0%
6. Continued Renal Replacement Therapy (CRRT): 1%.
Clinical outcome
Outcome Frequency Percentage
Hospital stay 97 97
death 3 3
Complications
The majority of the complications were related to respiratory and 
cardiovascular systems which are categorized as shown in Table 8.
DISCUSSION
In our study, we found that men were most affected with COVID-19 than 
women who were comparable with the research by J.M. Casas-Rojo and 
others. 2020 [6]. The majority of the subjects were found within the age 
Table 8: Complications of COVID‑19
Category Complications
Primary Cardio-pulmonary arrest, respiratory failure
Secondary ARDS, septic shock, COVID pneumonia, lung fibrosis.
Tertiary Co-morbid conditions which majorly include DM and 
HTN.
HTN: Hypertension, DM: Diabetes mellitus, ARDS: Acute respiratory distress 
syndrome
Table 6: CORADS scaling for COVID‑19
CO-RADS Level of suspicion 
for COVID‑19 
infection
CO-RADS 1 Highly unlikely Normal
CO-RADS 2 Unlikely Abnormal, infection other 
than COVID-19
CO-RADS 3 Indeterminate Not clear whether COVID is 
present or not
CO-RADS 4 High Abnormalities suspicion for 
COVID-19 infection
CO-RADS 5 Very Typical COVID-19
CO-RADS 6 PCR+
AQ4
Table 7: Table representing the CT severity score of 
COVID‑19 patients




Critically ill or death 3
CT: Computed tomography
AQ4
Figure 4: Line chart showing the diagnostic tests used for 
COVID‑19
AQ3
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CONCLUSION
From our study, based on the data collected from initial demographics 
of the patients till the discharge, we conclude that the frequency of 
infection is due to males’ predominance over females which means 
males are more infected than females. While the most affected people 
fall under the age group of 60–70 years with an average age of 65 years. 
HTN and diabetes mellitus were major among all other existing co 
morbidities. Most commonly occurring clinical presentations are fever 
and cough along with fatigue, loss of appetite, SOB, myalgia, and cold. 
Less common symptoms include loss of taste and smell, diarrhea, and 
vomiting. The most used and accurate diagnostic tests for COVID-19 
detection are RT-PCR and HRCT. Although there is no standard treatment 
for COVID-19, antiviral and antibiotics are majorly used followed by 
corticosteroids and immunosuppressants. Furthermore, vitamin and 
mineral supplements play a major role as a supportive treatment. Severe 
cases are treated majorly with oxygen supply and ventilation.
Majority of the patients recovered with the lowest death rate of 3% 
and average length of hospital stay with 15–20 days. Older age and 
existing chronic co morbid conditions may be the major risk factors for 
COVID-19 infection.
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